Fig. 3.
Fig. 3. Immunophenotypes of the hematopoietic cells from vector, Bcr-Abl, and Bcr-Abl/ΔSH2 mice. / Cells from PB, spleen, or BM were prepared and stained with the cell surface marker CD19, B220, and sIgM for B-lymphoid cells and Mac-1 for myeloid cells and analyzed on FACScaliber. (A) FACS profiles obtained from analysis of a GFP vector control mouse, BMT21.1 (top panel); a Bcr-Abl mouse, BMT21.6 (middle panel); and a Bcr-Abl/ΔSH2 mouse, BMT21.9 (bottom panel); on day 18 after BMT. (B) Expression of surface B220 and IgM on splenocytes from a normal mouse (i) and on GFP+ cells from PB of Bcr-Abl/ΔSH2 mouse, BMT5.16, on day 27 after BMT (ii). (C) FACS profiles of a vector mouse, BMT21.2 (top panel); and a Bcr-Abl/ΔSH2 mouse, BMT21.10 (bottom panel); on day 33 after BMT.

Immunophenotypes of the hematopoietic cells from vector, Bcr-Abl, and Bcr-Abl/ΔSH2 mice.

Cells from PB, spleen, or BM were prepared and stained with the cell surface marker CD19, B220, and sIgM for B-lymphoid cells and Mac-1 for myeloid cells and analyzed on FACScaliber. (A) FACS profiles obtained from analysis of a GFP vector control mouse, BMT21.1 (top panel); a Bcr-Abl mouse, BMT21.6 (middle panel); and a Bcr-Abl/ΔSH2 mouse, BMT21.9 (bottom panel); on day 18 after BMT. (B) Expression of surface B220 and IgM on splenocytes from a normal mouse (i) and on GFP+ cells from PB of Bcr-Abl/ΔSH2 mouse, BMT5.16, on day 27 after BMT (ii). (C) FACS profiles of a vector mouse, BMT21.2 (top panel); and a Bcr-Abl/ΔSH2 mouse, BMT21.10 (bottom panel); on day 33 after BMT.

Close Modal

or Create an Account

Close Modal
Close Modal